Strategic leadership New chairman Mark Pruzanski and recent board additions signal a strengthened governance and potential for rapid strategic partnering and licensing discussions with larger cardiovasculature-focused biotechs and pharma players.

Fundraising momentum Significant Series A funding and strong backing from Jeito Capital and OrbiMed indicate investor confidence and potential for collaboration on joint clinical programs, co-development deals, and strategic partnerships.

European US focus Ambition to become a global market leader in Europe and the US; opportunities for US-based CROs, contract development and manufacturing organizations, and translational partnerships to support global trials.

Cardiovascular niche Specialization in unaddressed heart failure subpopulations offers a clear entry point for targeted research collaborations, investigator-sponsored trials, and payer/real-world data partnerships to demonstrate value.

Early stage readiness Small team with substantial funding suggests a high pace of out‑licensing, advisory engagements, and co-development arrangements; ideal for lead generation around strategic collaborations and milestone-driven deals.